Novo Nordisk A/S (0QIU)
LSE
304.08
+7.65 (+2.58%)
Closed
Aug 24, 2026
Day's Range
297.95304.35
52 wk Range
225.00409.90
Financial Statements - 0QIU - Novo Nordisk A/S
Revenue
309.06B▲ 6.4%
Net Income
102.43B▲ 1.4%Net Margin 33.1%
EBITDA
150.65B▲ 8.8%
Free Cash Flow
28.98B▼ 58.4%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 309.06B | 290.40B | 232.26B | 176.95B | 140.80B | 126.94B |
| Cost of Goods | 58.78B | 44.52B | 35.76B | 28.44B | 23.65B | 20.93B |
| Gross Profit | 250.27B | 245.88B | 196.49B | 148.50B | 117.14B | 106.01B |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | 127.65B | 128.33B | 102.57B | 74.80B | 58.64B | 54.12B |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | 6.06B | -1.05B | 1.77B | -5.42B | 616M | -793M |
| Pre Tax Income | 130.54B | 127.19B | 104.67B | 69.06B | 59.08B | 53.13B |
| Income Tax | 28.10B | 26.20B | 20.99B | 13.53B | 11.32B | 10.99B |
| Net Income | 102.43B | 100.98B | 83.68B | 55.52B | 47.75B | 42.13B |
| EPS Basic | 23.06 | 22.67 | 18.67 | 12.26 | 10.395 | 9.025 |
| EPS Diluted | 23.03 | 22.63 | 18.62 | 12.22 | 10.37 | 9.005 |
| Basic Shares Outstanding | 4.44B | 4.45B | 4.48B | 4.53B | 4.59B | 4.66B |
| Diluted Shares Outstanding | 4.44B | 4.45B | 4.48B | 4.53B | 4.59B | 4.66B |
| Ebit | 134.74B | 128.83B | 105.21B | 69.44B | 59.36B | 53.52B |
| Ebitda | 150.65B | 138.41B | 112.94B | 82.04B | 64.75B | 60.21B |
| Net Income Continuous Operations | 102.43B | 100.98B | 83.68B | 55.52B | 47.75B | 42.13B |
| Minority Interests | - | - | - | - | - | - |
| Preferred Stock Dividends | - | - | - | - | - | - |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
